A Phase II Study of Afatinib (BIBW 2992) in Patients with Adenocarcinoma of the Lung and Activating EGFR/HER1 Mutations (LUX-Lung 2)

被引：0
|
作者：
Yang, Chih-Hsin [1 ]
Shih, Jin Yuan [1 ]
Su, Wu-Chou [2 ]
Hsia, Te-Chun [3 ]
Sequist, Lecia V. [4 ]
Chang, Gee-Chen [5 ]
Calvo, Roser
Cong, Xiuyu Julie
Shahidi, Mehdi
Miller, Vincent A. [6 ]
机构：
[1] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[2] Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan
[3] China Med Univ Hosp, Dept Internal Med, Taichung, Taiwan
[4] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[5] Taichung Vet Gen Hosp, Dept Internal Med, Taichung, Taiwan
[6] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S376 / S377
页数：2
相关论文
共 50 条
  • [41] Detection of Epidermal Growth Factor Receptor (EGFR) Mutations in Circulating Cell-Free DNA in Two Phase III Studies (LUX-Lung 3 and LUX-Lung 6) of Afatinib vs Platinum-Based Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer
    Wu, Yi-Long
    Sequist, Lecia
    Hu, Cheng-Ping
    Feng, Jifeng
    Lu, Shun
    Huang, Yunchao
    Li, Wei
    Hou, Mei
    Schuler, Martin
    Mok, Tony
    Yamamoto, Nobuyuki
    O'Byrne, Kenneth
    Hirsh, Vera
    Gibson, Neil
    Massey, Dan
    Kim, Miyoung
    Yang, James Chih-Hsin
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 142
  • [42] BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
    Li, D.
    Ambrogio, L.
    Shimamura, T.
    Kubo, S.
    Takahashi, M.
    Chirieac, L. R.
    Padera, R. F.
    Shapiro, G. I.
    Baum, A.
    Himmelsbach, F.
    Rettig, W. J.
    Meyerson, M.
    Solca, F.
    Greulich, H.
    Wong, K-K
    ONCOGENE, 2008, 27 (34) : 4702 - 4711
  • [43] BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
    D Li
    L Ambrogio
    T Shimamura
    S Kubo
    M Takahashi
    L R Chirieac
    R F Padera
    G I Shapiro
    A Baum
    F Himmelsbach
    W J Rettig
    M Meyerson
    F Solca
    H Greulich
    K-K Wong
    Oncogene, 2008, 27 : 4702 - 4711
  • [44] Phase III trial of afatinib vs erlotinib in patients (pts) with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8): EGFR molecular aberrations and survival outcomes
    Park, K.
    Li, W.
    Zhou, C.
    Felip, E.
    Cobo, M.
    Goss, G. D.
    Soria, J. -C.
    Syrigos, K.
    Kraemer, N.
    Chand, V. K.
    Solca, F.
    Lu, S.
    ANNALS OF ONCOLOGY, 2015, 26 : 135 - 135
  • [45] EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6
    Wu, Yi-Long
    Sequist, Lecia V.
    Hu, Cheng-Ping
    Feng, Jifeng
    Lu, Shun
    Huang, Yunchao
    Li, Wei
    Hou, Mei
    Schuler, Martin
    Mok, Tony
    Yamamoto, Nobuyuki
    O'Byrne, Kenneth
    Hirsh, Vera
    Gibson, Neil
    Massey, Dan
    Kim, Miyoung
    Yang, James Chih-Hsin
    BRITISH JOURNAL OF CANCER, 2017, 116 (02) : 175 - 185
  • [46] EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6
    Yi-Long Wu
    Lecia V Sequist
    Cheng-Ping Hu
    Jifeng Feng
    Shun Lu
    Yunchao Huang
    Wei Li
    Mei Hou
    Martin Schuler
    Tony Mok
    Nobuyuki Yamamoto
    Kenneth O'Byrne
    Vera Hirsh
    Neil Gibson
    Dan Massey
    Miyoung Kim
    James Chih-Hsin Yang
    British Journal of Cancer, 2017, 116 : 175 - 185
  • [47] HER-2 mutations in Chinese lung adenocarcinoma patients with negative EGFR mutations.
    Zhou, Caicun
    Li, Xuefei
    Zhao, Chao
    Su, ChunXia
    Ren, Shengxiang
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
    Nancy U. Lin
    Eric P. Winer
    Duncan Wheatley
    Lisa A. Carey
    Stephen Houston
    David Mendelson
    Pamela Munster
    Laurie Frakes
    Steve Kelly
    Agustin A. Garcia
    Susan Cleator
    Martina Uttenreuther-Fischer
    Hilary Jones
    Sven Wind
    Richard Vinisko
    Tamas Hickish
    Breast Cancer Research and Treatment, 2012, 133 : 1057 - 1065
  • [49] Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials
    Yang, J. C. -H.
    Sequist, L. V.
    Zhou, C.
    Schuler, M.
    Geater, S. L.
    Mok, T.
    Hu, C. -P.
    Yamamoto, N.
    Feng, J.
    O'Byrne, K.
    Lu, S.
    Hirsh, V.
    Huang, Y.
    Sebastian, M.
    Okamoto, I.
    Dickgreber, N.
    Shah, R.
    Maerten, A.
    Massey, D.
    Wind, S.
    Wu, Y. -L.
    ANNALS OF ONCOLOGY, 2016, 27 (11) : 2103 - 2110
  • [50] A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
    Lin, Nancy U.
    Winer, Eric P.
    Wheatley, Duncan
    Carey, Lisa A.
    Houston, Stephen
    Mendelson, David
    Munster, Pamela
    Frakes, Laurie
    Kelly, Steve
    Garcia, Agustin A.
    Cleator, Susan
    Uttenreuther-Fischer, Martina
    Jones, Hilary
    Wind, Sven
    Vinisko, Richard
    Hickish, Tamas
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 133 (03) : 1057 - 1065
12345